According to the lawsuit, throughout the Class Period, defendants made materially false and/or misleading statements regarding the Company’s:

• data from the sabizabulin Phase 3 trial and the Company’s interactions with the FDA;
• statements misleading its shareholders to believe that the data from the Phase 3 trial was sufficient to support Emergency Use Authorization (“EUA”) and even the submission of a New Drug Application (“NDA”) without any further studies; and
• filings which concealed the true risks faced by the Company in gaining approval for its EUA request

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Attorney Advertising. Prior results do not guarantee a similar outcome.